Apyx Medical Lowers Expense Outlook To $41.0 Million–$42.5 Million While Keeping Sales Target

AYON and international generator sales lifted the quarter, while manufacturing customers bought less.

Share
Apyx Medical Lowers Expense Outlook To $41.0 Million–$42.5 Million While Keeping Sales Target

Apyx Medical, which makes surgical devices for cosmetic surgery, lowered its 2026 operating-expense outlook to $41.0 million–$42.5 million from less than $45.0 million Thursday, while maintaining its sales forecast. Third-quarter revenue rose 9% to $14.0 million from $12.9 million a year earlier, and the loss attributable to stockholders narrowed.

AYON Gains Offset Manufacturing Decline

Surgical Aesthetics supplied approximately $13.0 million of quarterly revenue, up 17% from $11.1 million a year earlier. Domestic sales of AYON and international generator purchases drove the increase, partly offset by weaker domestic standalone-generator sales and lower sales of single-use handpieces globally.

The manufacturing business moved in the opposite direction. Revenue from agreements to make devices for other companies fell 42% to approximately $1.1 million from $1.8 million as existing customers reduced purchases. Apyx expects that business's annual revenue to decline as it focuses more on Surgical Aesthetics.

International revenue increased 22.1% to $4.327 million, while domestic revenue rose 4.0% to $9.703 million. For the first nine months, total sales reached $40.404 million, up 20.0% from $33.680 million.

APYX shares fell about 5% to $2.91 in Friday trading.

Less Cash Burn, Higher Quarterly Costs

Apyx's quarterly loss attributable to stockholders narrowed to $1.8 million, or $0.04 per share, from $2.0 million, or $0.05 per share. Operations consumed $1.6 million in cash, compared with $3.5 million a year earlier; the company attributed the improvement primarily to working-capital changes and the smaller loss. Cash and equivalents stood at $25.8 million on September 30.

Gross profit rose 8% to $9.0 million, but gross margin was nearly unchanged at 64.2%, versus 64.4%. Quarterly operating expenses increased to $9.6 million from $9.1 million: salaries and related costs rose $0.4 million and selling, general and administrative expenses rose $0.2 million, partly offset by a $0.2 million reduction in professional services.

Adjusted earnings before interest, taxes, depreciation and amortization turned positive at $0.4 million, compared with a $0.1 million loss a year earlier. Apyx's measure also excludes stock-based pay, which totaled $753,000 in the quarter.

The lower annual expense forecast accompanies an unchanged revenue target of $59.0 million–$60.0 million, versus $52.8 million in 2025. Apyx expects $54.0 million–$55.0 million from Surgical Aesthetics, compared with approximately $45.3 million last year, and approximately $5.0 million from manufacturing agreements, versus approximately $7.5 million. Its gross-margin target remains 63%–65%.

Power Liposuction Broadens AYON

AYON brings fat removal, contouring and skin tightening into one platform. Renuvion uses helium plasma to apply controlled heat to tissue; Apyx sells its hospital-surgery version as J-Plasma. The company primarily uses its own sales force in the U.S. and distributors abroad.

During the quarter, Apyx began broadly selling AYON's reusable power liposuction handpiece, which received FDA clearance earlier this year. AYON itself began its commercial launch in the third quarter of 2025.

“We estimate that approximately 70% of plastic surgeons use power liposuction, making this an important addition that broadens AYON’s appeal,” said Charlie Goodwin, Apyx Medical's president and chief executive officer.

Apyx also published a prospective Renuvion study in Plastic and Reconstructive Surgery — Global Open. Among six participants who completed six-month follow-up, treated tissue had 30% greater elastin fiber density and 34% less inflammation than untreated control areas.

The annual sales forecast calls for higher Surgical Aesthetics revenue and lower manufacturing revenue—the same split already visible in the third quarter.

Sources

More on Apyx Medical

All Apyx Medical (APYX) coverage →